Andrew Pumerantz, DO, FACP
Executive Director, Western Diabetes Institute, Associate Professor of Internal Medicine / Chief, Division of Infectious Disease
College of Osteopathic Medicine of the Pacific
Phone: 909-706-3779 | Fax: 909-620-1048
Join year: 2007
Pumerantz A, Muppidi K, Agnihotri S, Guerra C, Venketaraman V, Wang J, Betageri G. Preparation of liposomal vancomycin and intracellular killing of meticillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2011; 37: 140-144
Muppidi K, Wang J, Betageri G, Pumerantz AS. PEGylated Liposome Encapsulation Increases the Lung Tissue Concentration of Vancomycin. Antimicrob Agents Chemother 2011; 55(10): 4537-4542.
Muppidi K, Pumerantz AS, Wang J, Betageri G. Development and Stability Studies of Novel Liposomal Vancomycin Formulations. ISRN Pharmaceutics 2012; Volume 2012, doi:10.5402/2012/636743
Pumerantz AS. PEGylated Liposomal Vancomycin: A Glimmer of Hope for Improving Treatment Outcomes in MRSA. Pneumonia.Recent Pat Antiinfect Drug Discov 2012; Vol. 7, No. 3: 205-212.
Muppidi K, Pumerantz AS, Betageri G, Wang J. Development and Validation of a Rapid High-Performance Liquid Chromatography Method with UV Detection for the Determination of Vancomycin in Mouse Plasma. J Chromat Separation Techniq 2013; 4: 165.
Dr. Pumerantz has more than 25 years of experience spanning a spectrum of patient care, medical education, and research that focused in large part on the infectious complications of diabetes. He became alarmed by the realization that in spite of ongoing advances in biomedical research and drug development, successful diabetes management remained elusive. He looked at a prevailing care delivery system characterized by fragmentation and non-integration that paid more attention to the treatment of disease than to the achievement and maintenance of health. In addressing the need to redefine health care delivery in the face of exponentially growing diabetes pandemic, Dr. Pumerantz founded, and is Executive Director of, the Western Diabetes Institute (WDI). The WDI is an integrated practice and research unit whose mission is to deliver person-centered, community-oriented, comprehensive, and integrated, cross-disciplinary, team-based care to people living with diabetes and its associated multimorbidities. As an academic health center, WDI provides health professions students from multiple disciplines with education and training in longitudinal, team-based care that is fundamental to improving the health and well-being of a large and growing number of people living with one or more chronic, complex diseases. The WDI consists of various specialty units, including the Endocrine and Insulin Titration Clinics; the Heart and Vascular Center; the Center for Kidney Disease and Hypertension; the Center for Fitness and Function; the Diabetes Education and Nutrition Unit; the Care Coordination Unit; the Behavioral Health Unit; and the Research Unit. The WDI also collaborates with the Dental and Eye Care Centers of WesternU. Dr. Pumerantz developed a novel composite health index to serve as a balanced scorecard and lingua franca that promote shared decision-making aligned with the patient’s health goals. The WDI manages a research registry that enables measurement of outcomes and the costs of delivering those outcomes to patients. WDI is piloting their innovative diabetes care model with health plans, including California’s largest managed Medi-Cal (Medicaid) plan. Dr. Pumerantz is the medical advisor for ClickMedix, a global mobile health (mHealth) social enterprise founded by faculty and students from Massachusetts Institute of Technology and Carnegie Mellon University to increase capacity of physicians and health organizations to serve more patients (http://clickmedix.com/).
In 2007, Dr. Pumerantz arrived at WesternU as Associate Professor of Internal Medicine and COMP’s Division Chief of Infectious Disease. He initiated sweeping curricular changes moving from traditional lecture-based delivery to a more case-based and interactive learning design to foster critical-thinking and diagnostic acumen. He redesigned the infectious disease components and helped guide the broader internal medicine curricular redevelopment. In 2008 with WesternU pharmaceutical scientists, Drs. Jeffrey Wang and Guru Betageri, Dr. Pumerantz co-invented PEGylated liposomal vancomycin (PLV) and spent 5 years as the cross-disciplinary team’s Principal Investigator evaluating its biodistribution and drug delivery in treating MRSA pneumonia. From 2008 to 2012, Dr. Pumerantz served as Department Chair of Internal Medicine during which time he established the Divisions of Endocrinology, Diabetes, and Metabolism; Nephrology and Hypertension; Infectious Disease; and Cardiovascular Disease. In 2012, he received the first COMP Faculty Award for Outstanding Cross Campus Colleague. It was during his tenure as Internal Medicine Chair, that Dr. Pumerantz established the WDI. He has spoken internationally on PLV and disruptive innovation in diabetes care.
Dr. Pumerantz holds an AB from Occidental College in Los Angeles, and a DO from Philadelphia College of Osteopathic Medicine. He trained in internal medicine at Beth Israel Medical Center in New York City where he also served as a Chief Medical Resident. Dr. Pumerantz completed infectious diseases fellowship at Yale School of Medicine. He is a Fellow of the American College of Physicians.